Ryan Gentzler headshot

Ryan D. Gentzler

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
MD, Temple University School of Medicine
Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
Fellowship, Hematology-Oncology, Northwestern Memorial Hospital, Chicago, IL

Dr. Gentzler received his MD degree from Temple University School of Medicine and completed his internal medicine internship and residency at Thomas Jefferson University Hospital. He also earned a master’s degree in pharmacology during his residency with a focus on clinical investigation supported by the NIH K30 Clinical Research Curriculum Award. He completed his hematology/oncology fellowship at Northwestern University.

Dr. Gentzler’s clinical focus is the treatment of patients with lung cancer and other thoracic malignancies. His research is centered around the development of novel therapies for lung cancer. 

He is an active investigator on many active clinical trials, serves as the director of the Thoracic Oncology Clinical Research Program at UVA and chairs the UVA Cancer Center’s Lung Cancer Translational Research Team. Dr. Gentzler is also director of the UVA Cancer Center Protocol Review Committee, which provides scientific review and oversight of cancer research conducted at UVA. On a national level, he has leadership roles in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) and Thoracic Clinical Trials Working Group for the Hoosier Cancer Research Network (HCRN). He is also an active member of the ECOG-ACRIN cooperative group. He has received grants from the NIH and Lung Cancer Research Foundation, is the PI on the NCI-sponsored ETCTN 10399 clinical trial for patients with small cell lung cancer and is site PI on numerous other lung cancer clinical trials at the University of Virginia.

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC)
Source: Daiichi Sankyo, Inc
May 20, 2021 – May 19, 2024
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Source: Mirati Therapeutics, Inc.
April 06, 2021 – April 05, 2024
CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Source: Alliance Foundation Trials, LLC.
March 25, 2021 – March 24, 2024
Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer
Source: Johns Hopkins University
March 15, 2021 – March 14, 2024
MD-INMD-HO - Gentzler - Helsinn ANAM 17-20
Source: Psi Pharma Support America Inc.
April 15, 2019 – April 14, 2023
Experimental Therapeutics Clinical Trials Network (ETCTN)
Source: Johns Hopkins University
May 01, 2020 – February 28, 2023
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFRmutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor ECTN 9903
Source: Johns Hopkins University
February 01, 2017 – February 28, 2023
A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Source: Johns Hopkins University
September 15, 2017 – February 28, 2023
A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non¿Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Source: Takeda Pharmaceuticals
February 04, 2020 – February 03, 2023
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer
Source: Jounce Therapeutics, Inc.
October 16, 2019 – October 15, 2022
A phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Source: Hoosier Cancer Research Network, Inc.
September 10, 2019 – September 09, 2022
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
Source: Hoosier Cancer Research Network, Inc.
August 19, 2019 – August 18, 2022
MD-INMD-HO A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Source: Merck Sharp & Dohme Corp.
May 18, 2015 – May 31, 2022
MD-INMD-HO Gentzler Merck MK 3475-671-0013
Source: Merck Sharp & Dohme Corp.
April 19, 2018 – April 18, 2022
Source: ECOG-ACRIN Cancer Research Group
March 01, 2019 – February 28, 2022
MD-INMD-HO Phase I/II study of carboplatin/nab-paclitaxel and pembrolizumab for patients with advanced non-small cell lung cancer (NSCLC)
Source: Hoosier Cancer Research Network, Inc.
February 16, 2016 – February 15, 2022
MD-INMD-HO - Gentzler - Takeda AP32788-15-101
Source: PRA Health Sciences
January 16, 2019 – January 15, 2022
Real-time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with EGFR mutations or ALK Rearrangements
Source: Pfizer Inc.
December 20, 2019 – December 31, 2021
A phase II trial of concurrent chemoradiation with consollidation Pembrolizumab for the treatment of Inoperable or unresectable stage III non-small cell lung cancer (NSCLC): LUN14-179
Source: Allakos, Inc.
July 01, 2016 – November 07, 2021
MD-INMD-HO A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During of After Receiving at Least One Prior Systemic Regimen
Source: Bristol-Myers Squibb Company
October 13, 2014 – September 30, 2021
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Source: ECOG-ACRIN Cancer Research Group
June 11, 2018 – June 10, 2021
Source: ECOG-ACRIN Cancer Research Group
May 01, 2016 – April 30, 2021
MD-INMD-HO Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Source: ECOG-ACRIN Cancer Research Group
January 14, 2015 – March 05, 2021
NCTN High Performance Site Initiative
Source: PPD Development, Inc.
November 01, 2017 – December 31, 2020
Source: ECOG-ACRIN Cancer Research Group
March 01, 2019 – October 30, 2020



Cancer Center Protocol Review Committee


ASCO Annual Meeting Scientific Program Committee


Excellence in Research Department of Medicine, UVA, 2020

Recognition of Outstanding Patient Experience, UVA Health, 2018, 2019, 2020

Excellence in Clinical Care Award, Department of Medicine, UVA, 2018

Compassionate Care Award, Northwestern University Women’s Board, 2014

Excellence in Teaching Award, Dept. of Medicine, Northwestern University, 2013

The Kowlessar Award for Excellence in General Medicine, Thomas Jefferson University Hospital, 2011

Emmanuel M. Weinberger Award for Hematology/Oncology Temple University School of Medicine, 2008